Luteinizing Hormone (LH) Supplementation in Gonadotropin-releasing Hormone (GnRH) Antagonist Cycles
- Conditions
- Ovarian Stimulation
- Registration Number
- NCT01037699
- Lead Sponsor
- Instituto Valenciano de Infertilidad, IVI VALENCIA
- Brief Summary
To analyse the impact on cycle outcome of LH supplementation in ovarian stimulation controlled with a GnRH antagonist in two ages groups: patients upto 35 years old, and patients aged between 36 and 39 years old.
- Detailed Description
All patients received an oral contraceptive pill with 0.030 mg of ethinyl-estradiol and 3.0 mg of drospirenone the cycle prior to ovarian stimulation. On the second day of menstruation, patients started ovarian stimulation as follows:
Patients \< 36: 225 IU/day of recombinant FSH (FSH alone group) or 150 IU of rFSH and 75 IU of rLH/day (FSH+LH group) for 5 days. On day 6, a 0.25 mg/day dose of the GnRH antagonist Cetrorelix is added until the day of rCG administration.
Patients 36-39: Initial dose of 300 IU of rFSH /day (FSH alone group)) or 225 IU of rFSH and 75 IU of rLH/day (FSH + LH group) for 5 days. On day 6, a 0.25 mg/day dose of the GnRH antagonist Cetrorelix is added until the day of rCG administration.
A maximum of 3 embryos were transferred on day 3 of embryo development.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 720
- 1st-2nd IVF cycle.
- Age until 39 years old
- BMI: 18-29.9.
- Basal FSH < 12 IU/L
- LH:FSH > 2 (PCO)
- Low response background (< 5 oocytes)
- Endometrioma
- Recurrent pregnancy loss
- Any preimplantational genetic diagnosis indication
- Any systemic, metabolic or endocrinological disorder.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Implantation rate 4 weeks after embryo transfer
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
IVI Valencia
🇪🇸Valencia, Spain